Evidence map›Paper›PMID 31152247›Full record

ArticleBasic research in cardiology2019

E2f1 deletion attenuates infarct-induced ventricular remodeling without affecting O-GlcNAcylation.

Sujith Dassanayaka, Kenneth R Brittian, Andrea Jurkovic, Lauren A Higgins, Timothy N Audam, Bethany W Long, Linda T Harrison, Giuseppe Militello, Daniel W Riggs, Mitali G Chitre and 4 more

Open access · greenAbstract read
In one paragraph

Article in Basic research in cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. The E2F family: a ray of dawn in cardiomyopathy.Molecular and cellular biochemistry · 2025
    Review
  4. Matricellular protein CCN1 promotes collagen alignment and scar integrity after myocardial infarction.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Regulation of cardiac O-GlcNAcylation: More than just nutrient availability.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Sujith DassanayakaDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Kenneth R BrittianDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Andrea JurkovicDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Lauren A HigginsDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Timothy N AudamDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Bethany W LongDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Linda T HarrisonDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Giuseppe MilitelloDivision of Cardiovascular Medicine, Department of Medicine, Cardiovascular Innovation Institute, University of Louisville, Louisville, KY, USA.
Daniel W RiggsDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Mitali G ChitreDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Shizuka UchidaDivision of Cardiovascular Medicine, Department of Medicine, Cardiovascular Innovation Institute, University of Louisville, Louisville, KY, USA.
Senthilkumar MuthusamyDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Anna M GumpertDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Steven P JonesDivision of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA. Steven.P.Jones@Louisville.edu.ORCID http://orcid.org/0000-0001-5376-8089
University of Louisville · US

Funding

Tumor Necrosis Factor Modulation of CPCsP01HL078825 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2005 to 2021
$37.6M
TBDP30GM127607 · NIGMS · UNIVERSITY OF LOUISVILLE · PI HILL, BRADFORD GUY · 2018 to 2022
$6.3M
Regulation of Metabolic Genes in the HeartR01HL131647 · NHLBI · UNIVERSITY OF LOUISVILLE · PI JONES, STEVEN P · 2016 to 2019
$2.2M
NHLBI NIH HHS P01 HL078825NHLBI NIH HHS R01 HL131647NIGMS NIH HHS P30 GM127607NIH HHS P01 HL078825NIH HHS P30 GM127607NIH HHS R01 HL131647
6 · The paper itself

Abstract

Several post-translational modifications figure prominently in ventricular remodeling. The beta-O-linkage of N-acetylglucosamine (O-GlcNAc) to proteins has emerged as an important signal in the cardiovascular system. Although there are limited insights about the regulation of the biosynthetic pathway that gives rise to the O-GlcNAc post-translational modification, much remains to be elucidated regarding the enzymes, such as O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), which regulate the presence/absence of O-GlcNAcylation. Recently, we showed that the transcription factor, E2F1, could negatively regulate OGT and OGA expression in vitro. The present study sought to determine whether E2f1 deletion would improve post-infarct ventricular function by de-repressing expression of OGT and OGA. Male and female mice were subjected to non-reperfused myocardial infarction (MI) and followed for 1 or 4 week. MI significantly increased E2F1 expression. Deletion of E2f1 alone was not sufficient to alter OGT or OGA expression in a naïve setting. Cardiac dysfunction was significantly attenuated at 1-week post-MI in E2f1-ablated mice. During chronic heart failure, E2f1 deletion also attenuated cardiac dysfunction. Despite the improvement in function, OGT and OGA expression was not normalized and protein O-GlcNAcyltion was not changed at 1-week post-MI. OGA expression was significantly upregulated at 4-week post-MI but overall protein O-GlcNAcylation was not changed. As an alternative explanation, we also performed guided transcriptional profiling of predicted targets of E2F1, which indicated potential differences in cardiac metabolism, angiogenesis, and apoptosis. E2f1 ablation increased heart size and preserved remote zone capillary density at 1-week post-MI. During chronic heart failure, cardiomyocytes in the remote zone of E2f1-deleted hearts were larger than wildtype. These data indicate that, overall, E2f1 exerts a deleterious effect on ventricular remodeling. Thus, E2f1 deletion improves ventricular remodeling with limited impact on enzymes regulating O-GlcNAcylation.

Indexed as

Ventricular Function, LeftVentricular RemodelingAnimalsbeta-N-AcetylhexosaminidasesCapillariesCoronary VesselsDisease Models, AnimalE2F1 Transcription FactorFemaleGene DeletionGlycosylationMaleMice, Inbred C57BLMice, KnockoutMyocardial InfarctionMyocardiumbeta-N-AcetylhexosaminidasesE2f1 protein, mouseE2F1 Transcription Factorhexosaminidase CN-AcetylglucosaminyltransferasesOgt protein, mouseGlycosylationHeart failureHexosamine biosynthetic pathwayMetabolism

Identifiers

PMID31152247
PMCPMC7278029
OpenAlexW2948013290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.